Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

320.08 1.03 −0.32%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a

Penumbra, Inc. (PEN) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Penumbra, Inc. (PEN) trades at a P/B ratio of 8.0×. Over the past ten years it has ranged from 0.0× (September 2015) to 17.4× (April 2021); the current reading is higher than 36% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 8.5× 6.32%
FY2024 8.0× (0.01%)
FY2023 8.0× (4.86%)
FY2022 8.4× (24.32%)
FY2021 11.1× 12.83%
FY2020 9.8× (16.51%)
FY2019 11.8× 19.03%
FY2018 9.9× 32.71%
FY2017 7.4× 1.65%
FY2016 7.3× 163.77%

Quarterly newest first

Period P/B ratio Change
Sep 2026 7.9× (2.42%)
Jun 2026 8.1× (7.23%)
Mar 2026 8.8× 3.24%
Dec 2025 8.5× 16.33%
43 more quarters

Against its own ten years

Low 0.0× High 17.4×
Ten-year median 8.6×
Current reading's percentile 30

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on PEN